NR4A1 and breast cancer: According to the European Society for Medical Oncology (ESMO) guidelines, CDK4/6 inhibitors in combination with endocrine therapy are recommended as the standard of care for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer.